drugset / Trial / NCT04055844
Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in AML/MDS
Phase 2
Completed
14 enrolled
Masonic Cancer Center, University of Minnesota
Incyte Corporation · collab
NaSequentialOpen-labelTreatment
Summary
This is a multi-center, single-arm, open-label, phase II trial for the frontline treatment of relapsed AML or MDS following allo-HCT. Eligible subjects will receive up to 4 cycles of combined modality treatment. The number of cycles depends on response, toxicity, and the remaining cell dose.
Timeline
- Start
- 2020-02-17
- Primary completion
- 2022-09-06
- Completion
- 2022-09-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Decitabine | Small molecule | 20 mg/m2 | Intravenous |
| Subject | Ruxolitinib | Small molecule | 5 mg | Oral |
| Subject | Ruxolitinib | Small molecule | 10 mg | Oral |